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Abstract This study assessed cardiovascular disease
risk factors in three groups of human subjects aged
20–34 [young, 20 male (M)/33 female (F)], 60–74
(aged, 29M/29F), and > 90 years (nonagenarian,
47M/50F). Components of the metabolic syndrome,
cardiovascular disease, and markers of inflammation
and oxidative stress were assessed. Nonagenarians
weighed less than the two other groups (P<0.001);
however, there was no difference in percent fat among
the three groups. Aged individuals had the highest
prevalence of the metabolic syndrome (P<0.001)
according to the Adult Treatment Panel III classifica-
tion. Both fibrinogen and homocysteine concentra-
tions were significantly higher in the nonagenarians
compared to younger groups. However, there were no
significant differences b e t w e e ng r o u p si nf a s t i n g
insulin, high sensitive C-reactive protein, and plas-
minogen activator inhibitor 1 concentrations. There
were also no relationships between inflammation/
oxidative stress and the metabolic syndrome or
cardiovascular disease although nonagenarians appear
to be protected from oxidative damage to DNA.
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The average life expectancy in the United States is
77 years, and in the western world the chance of living
to 100 is 1 in 10,000 (Oeppen and Vaupel 2002;P e r l s
et al. 2002). Individuals achieving this longevity
appear to delay or even escape various age-related
diseases such as type 2 diabetes mellitus (T2DM) and
cardiovascular disease (CVD) that typically develop at
younger ages (Perls et al. 2000). These individuals may
therefore possess genetic and physiological traits that
contribute to their exceptional longevity.
Cardiovascular disease is one of the leading causes
of death in the westernized world (Kahn et al. 2005).
The American Heart Association reports that 84% of
individuals diagnosed with CVD are over the age of
65 years. The development of CVD is preceded by
traits of the metabolic syndrome, a clustering of risk
factors for CVD including obesity, dyslipidemia,
hypertension, insulin resistance, and glucose intoler-
ance (Ferrannini et al. 1991; World Health Organiza-
tion1999).Someindividualswithexceptionallongevity
are seldom affected by the age-related alterations in
CVD risk, althoughthe mechanismsresponsible for this
younger profile are unknown (Keys et al. 1952;
National Health and Nutrition Examination Surveys
1987;F e r r a n n i n ie ta l .1991;P a o l i s s oe ta l .1995,
1997; Roubenoff and Hughes 2000; Ryan 2000; Perls
et al. 2002;B a r z i l a ie ta l .2003).
Cardiovascular disease is tightly associated with
inflammation (Ross 1999). Consistent with this
paradigm is the recognition that, in addition to the
well-recognized CVD risk factors including lipids and
blood pressure, other factors, including hemostasis
factors, markers of inflammation and oxidative stress,
and acute phase proteins, are of importance. Circulat-
ing concentrations of these markers increase with age
and are predictive of future CVD events (Kannel et al.
1987; Ridker et al. 1998a, b, 2004; Pearson et al.
2003; Devaraj et al. 2005). Assessment of such
factors may help to determine an individual’s “bio-
logical age” as opposed to their chronological age.
Thus, individuals displaying exceptional longevity
may be considered biologically younger than their
chronological age and this may contribute to their
extended lifespan (Fig. 1). This study tests the
hypothesis that nonagenarians have levels of risk
factors for CVD comparable to aged subjects and will
present with less inflammation and oxidative stress.
Methods
Subjects
The subjects included in this analysis represent a
subset of the Louisiana Healthy Aging Study (LHAS)
funded as a program project from the National
Institute on Aging (Frisard et al. 2007). In this
project, extensive data were collected in three groups
of individuals aged 20–34, 60–74, and >90 years.
Subjects were excluded if they had been diagnosed
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Fig. 1 Biosignatures of aging. As individuals age, cardiovas-
cular disease (CVD) risk factors and biosignatures such as
fasting insulin and C-reactive protein (CRP) increase. These
markers can be used to assess biological age. Accordingly, for a
given chronological age, individuals may have values indicat-
ing younger, similar, or older biological age (left panel, dotted
lines, shown with prediction limits). For example, an individual
aged ~70 years may have values that are much lower than
predicted, indicating they are younger than their chronological
age. We hypothesize in this study that nonagenarians are
biologically younger than their chronological age (right panel)
and this contributes to their exceptional longevity
68 AGE (2009) 31:67–75with diabetes or had elevated fasting blood sugar
(>125 mg/dl), thyroid disease, unstable CVD or
mental health problems requiring drug treatment.
Nonagenarians were additionally excluded if they
had a heart attack or stroke in the 3 months prior to
testing, severe high blood pressure, blood vessel
aneurysm, taking certain medications used for myas-
thenia gravis or had uncontrolled asthma, an asthma-
like condition or emphysema/chronic obstructive
pulmonary disease (COPD). The study was approved
by the Institutional Review Boards of the Pennington
Biomedical Research Center and the Louisiana State
University Health Sciences Center, New Orleans.
Body composition assessment
Weight was measured to ±0.1 kg with an electronic
scale (Detecto, Webb City, MO). Height was measured
to ±0.5 cm with a wall-mounted stadiometer (Holtain;
Crymych, Dyfed, UK), and body mass index (BMI)
was calculated as weight divided by height squared
(kg/m
2). Waist circumference was measured with a
standard tape measure while the subject was in the
standing position. Whole body composition was
estimated by dual-energy X-ray absorptiometry
(DXA) (Hologics, QDR 4500A, Bedford, MA).
Blood pressure assessment
Blood pressure was measured in a quiet room with
minimal temperature fluctuations following a 5 min
rest period. All measurements were taken twice (and
averaged) on the participant’s right arm with a manual
sphygmomanometer (Baum, Coplaque, NY).
Blood and urinary analyses
Blood samples were drawn in fasting conditions for
serum lipids with HDL-C measured by a Sigma
Chemical (St. Louis, MO) kit whereas LDL-C was
calculated using the Friedewald equation (Friedewald
et al. 1972). Glucose was analyzed using a glucose
oxidase electrode (Beckman Synchron CX7, Brea,
CA), and insulin, high sensitivity C-reactive protein
(hsCRP), and homocysteine were measured by
immunoassays on a DPC 2000 (Diagnostic Product
Corporation, Los Angeles, CA). The HOMA index
was calculated as fasting glucose (mmol/L) × fasting
insulin (μU/mL)/22.5. Factor VII activity and fibrinogen
were measured on an ACL 3000 (Brea, CA). Factor VII
was expressed as percent relative to serial dilution of
pooled plasma (Clauss 1957). Plasminogen activator
inhibitor 1 (PAI-1) was measured by enzyme-linked
immunosorbent assay (ELISA) using a kit from
American Diagnostica (Stamford, CT). As indices of
oxidative stress, urinary isoprostanes were measured
using liquid chromatography with mass spectrometry
(Davies et al. 2006), serum protein carbonyl content
using a modified 2,4-dinitrophenylhydrazine (DNPH)
technique (Mates et al. 2000) and DNA fragmentation
by single cell gel electrophoresis (Comet and FLARE
assay) (Deutsch et al. 2001). Interleukin six (IL-6)
was measured by ELISA using a kit from LINCO
(St Charles, MO) and run on a Luminex IS 100
(Austin, TX).
Metabolic syndrome classification
Metabolic syndrome was defined according to the
Adult Treatment Panel III (ATPIII) definition if at least
three or more of the following criteria were present: (1)
waist circumference >102 cm in men or >88 cm in
women, (2) Triglycerides >150 mg/dl or treatment for
hypertriglyceridemia, (3) HDL cholesterol <40 mg/dl
for men or <50 mg/dl for women or treatment for
dyslipidemia, (4) Blood pressure >130/85 mmHg or
documented use of antihypertensive therapy, (5)
Fasting glucose concentration >100 mg/dl.
Statistical analysis
Data are presented as means ± SEM. Data analyses
were performed using SAS version 9.1.3 (SAS
Institute, Cary, NC). Insulin and triglyceride were
log transformed to correct for skewing but are
presented using untransformed values. Age group
and sex effects for subject characteristics were tested
using a two-way factorial ANOVA (analysis of
variance) and BMI was included as a covariate in
the two-way ANOVA model when testing for the
cardiovascular risk factors. The statistical significance
for all multiple comparisons was adjusted with respect
to the Tukey-Kramer method to control for Type I
error rate. The level of significance for all statistical
tests was set at P<0.05. Pearson correlation coef-
ficients were used to assess relationships between risk
factors for CVD, inflammatory markers, and oxidative
stress.
AGE (2009) 31:67–75 69Results
A total of 208 participants were enrolled in the
present study. The three groups will be referred to as
young [20 male (M), 27±1 years; 33 female (F),
28±1 years], aged (29M, 69±1; years 29F, 69±
1 years) and nonagenarian (47M, 93±0.3 years;
50F, 92±0.3 years). The young group consisted of
15 white males, 24 white females, 5 black males,
and 9 black females. The aged group consisted of
26 white males, 23 white females, 1 black male, 5
black females, 2 “other” males, and 1 other
female. The nonagenarian group consisted of 38
white males, 47 white females, 2 black males, 1
black female, 7 other males, and 2 other females.
Over the 3 years necessary to recruit the 208
volunteers described, another 177 were recruited in
the program. Sixty-five nonagenarians were ex-
cluded for the presence of T2DM (N=24) and/or
thyroid disorders (N=41) and 75 individuals chose
not to come for the 7-h testing at our clinical facility.
There were also 25 individuals excluded from the
aged group (8 with T2DM, 10 with thyroid disease,
and 7 unavailable for 7-h testing) and 12 individuals
excluded from the young group (3 with T2DM, 2
with thyroid disease, 1 with pregnancy, and 6
unavailable for 7-h testing). Data for hsCRP, factor
VII, fibrinogen, homocysteine, and PAI-1 was
available for 200, 198, 198, 199, and 196 subjects,
respectively. Data for IL-6, isoprostanes, protein
carbonyls, and the comet assays were available for
133, 86, 199, and 189 subjects, respectively.
Body composition
Body composition characteristics of the subjects in
the three age groups are displayed in Table 1. In all
three age groups, males weighed significantly more
than females (P<0.001) and females had higher
percent body fat than males (P<0.001). Nonagenar-
ians weighed significantly less than either the young
or the aged group (both, P<0.001) and had a
significantly lower BMI (both, P<0.001). Thirty
percent of the young group, 38% of the aged group,
and 8% of the nonagenarians were obese (BMI >30)
whereas 30%, 53% and 43% were overweight (30>
BMI >25), respectively.
Metabolic syndrome
Thirteen percent of the young group, 63% of the aged
group, and 35% of the nonagenarians were classified
Table 1 Subject characteristics. Values are presented as means + SEM. Mean values within a row not sharing a common lower case
letter are significantly different (P<0.05) for pair-wise comparisons by age group and sex when interaction is significant. Non.
Nonagenarian, BMI body mass index, A×Sage group by sex interaction
Young
(20-34 years)
Young vs
Aged
Aged
(60-74 years)
Aged vs
Non.
Nonagenarian
(>90 years)
Young vs
Non
Statistical significance of
difference between means
Men Women P value Men Women P value Men Women P value Age
group (A)
Sex (S) A × S
n=20 n=33 n=29 n=29 n=47 n=50
Age (years) 27±1 28±1 69±1 69±1 93±0.3 92±0.3
Height (cm) 177±1 164±1 0.12 176±1 161±2 <0.001** 170±1 156±1 <0.001** <0.001** <0.001** 0.81
Weight (kg) 90±5 74±4 0.84 90±2 78±3 <0.001** 72±1 60±2 <0.001** <0.001** <0.001** 0.47
BMI
(kg/m
2)
29±2 27±1 0.30 29±1 30±1 <0.001** 25±0.4 25±1 <0.001** <0.001** 0.53 0.43
Body fat
(%)
22±2 a 35±1 b <0.001** 28±1 c 41±1 d 0.02* 27±1 ce 35±1 bf 0.02* <0.001** <0.001** 0.03*
Fat Free
mass (kg)
69±2 a 47±1 b 0.22 65±1 ac 46±2 bd <0.001** 52±1 e 38±1 f <0.001** <0.001** <0.001** 0.006*
Fat mass
(kg)
21±3 27±2 0.01* 25±2 32±2 <0.001** 20±1 22±1 0.19 <0.001** <0.001** 0.21
*P<0.05, ** P<0.001
Table 1 Subject characteristics. Values are presented as means +
SEM. Mean values within a row not sharing a common lower
case letter are significantly different (P<0.05) for pair-wise
comparisons by age group and sex when interaction is
significant. Non. Nonagenarian, BMI body mass index, A×S
age group by sex interaction
70 AGE (2009) 31:67–75as having the metabolic syndrome. Individuals in the
aged group had, on average, a significantly greater
number of components of metabolic syndrome than
the other two groups (Fig. 2, P<0.001). A greater
number of nonagenarians were taking medication to
treat blood pressure while the same number of
individuals in the two older groups was taking
medication to treat dyslipidemia. Average values for
individual components of the metabolic syndrome for
males and females are displayed in Fig. 3.A s
expected, men had greater waist circumference and
lower HDL-C concentrations than females (both, P<
0.001). In addition, males also had slightly higher but
significant diastolic blood pressure than females (P=
0.013). The two older groups had significantly larger
waist circumference (P<0.001), higher systolic blood
pressure (P<0.001), and higher fasting glucose than
the young group (P<0.001 for aged vs young, and P=
0.002 for nonagenarian vs young). Triglycerides were
also significantly higher for females in the two older
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Fig. 3 Age-related differences in individual components of the metabolic syndrome separated by sex. a Age group effect, b sex effect,
c age group × sex interaction. Older and oldest females are greater than young
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was log transformed (both P<0.001).
CVD risk factors
CVD risk factors are listed in Table 2. There were no
significant differences b e t w e e ng r o u p si nf a s t i n g
insulin, HOMA index, hsCRP, and PAI-1 concen-
trations nor were there any effects of sex. Males had
higher homocysteine plasma concentrations than
females(P=0.008). Among the three age groups, the
nonagenarians had higher homocysteine plasma con-
centrations compared to the young and the aged
groups (both P<0.001). There were significant age by
sex interactions for factor VII activity (P=0.04) and
fibrinogen (P=0.001). Females of the aged group had
higher factor VII activity than males in the same
group (P=0.008). However, factor VII activities for
males among the three age groups did not differ.
Females in the young group had significant lower
factor VII than females in the aged group (P=0.008).
For fibrinogen, there were no sex differences for the
aged and nonagenarian groups while the young group
showed a significant difference between the sexes
(P=0.001). Males of the young group had less
fibrinogen than either males in the aged (P=0.002)
or males in the nonagenarian (P<0.001) groups.
Females in the nonagenarian group had higher
fibrinogen than females in the young (P=0.04) and
the aged groups (P<0.001).
Markers of inflammation and oxidative stress
Markers of inflammation and oxidative stress are also
listed in Table 2. There were no significant differ-
ences in urinary isoprostanes, protein carbonyls, or
DNA fragmentation as measured by the comet assay
between the three groups. Interestingly, females had
higher urinary isoprostanes than males (P<0.002).
Also, the aged group had significantly higher DNA
fragmentation measured by the FLARE assay than
both the nonagenarians (P=0.01) and the young
individuals (P=0.02). There was a tendency (P=
0.10) for higher IL-6 concentrations in the aged
compared to the nonagenarians although this did not
reach significance. Finally, there were no significant
relationships between any markers of inflammation
and oxidative stress and any of the components of the
metabolic syndrome.
Discussion
These results indicate that risk factors for CVD in
nonagenarians are not elevated in proportion to age
when compared to individuals aged 60–74. Our
findings support the hypothesis that, as previously
observed in centenarians, nonagenarians may be
biologically young and protected from age-related
disease—a factor that may contribute to their longev-
ity. Contrary to our hypothesis, inflammation and
oxidative stress were not significantly related to the
components of the metabolic syndrome and/or CVD
risk factors, although they were not elevated in the
nonagenarians compared to the younger individuals. In
fact, oxidative damage to DNA was significantly
higher and IL-6 tended to be higher in the aged group
compared to the nonagenarians and the young individ-
uals. Whether the relatively low levels of inflammation
and oxidative stress in nonagenarians confer some
resistance to disease remains to be shown.
The aged group had the highest prevalence of the
metabolic syndrome. When comparing individual com-
ponents of the metabolic syndrome in nonagenarians to
the aged group, nonagenarians had mostly “better”
health values except for systolic blood pressure, which
was similar in the two groups. In addition to the widely
recognized risk factors for CVD, there are a number of
emerging biomarkers also becoming widely accepted,
such hsCRP, fibrinogen, homocysteine, and PAI-1
(Devaraj et al. 2005). In our study, except for
fibrinogen and homocysteine concentrations, nonage-
narians had comparable levels of CVD markers to
those in the younger groups. Specifically, nonagenar-
ians had comparable CRP and PAI-1 concentrations
and factor VII activities to the young individuals. PAI-
1 is the primary inhibitor of fibrinolysis, and factor VII
is a clotting factor that promotes thrombosis. Each of
these markers has been demonstrated to be predictive
of future coronary events and, in fact, CRP and PAI-1
are better markers of future disease than fibrinogen or
homocysteine (Kannel et al. 1987; Ridker et al.
1998b,2004; Thogersen et al. 1998). Overall, this study
supports the hypothesis that nonagenarians may be
protected from age-related disease.
Inflammation and oxidative stress are related
directly to the progression of atherosclerosis (Wass-
mann and Nickenig 2003). It was expected that
individuals with increased risk for CVD would also
have increased inflammatory markers and higher
AGE (2009) 31:67–75 73oxidative damage. Only oxidative damage to DNA
was found to be significantly higher in the aged group
than either of the other two groups, indicating that
nonagenarians may be protected from the age-related
increase in DNA damage. However, the finding that
inflammation and oxidative damage were not related
to cardiovascular risks in the observed population
therefore does not support the hypothesis that such
factors are implicated in the development of the
metabolic syndrome and CVD. On the contrary, the
absence of increased inflammation and oxidative
stress in the nonagenarians, coupled with levels of
CVD markers comparable to younger individuals
suggests that nonagenarians may be biologically
younger than their chronological age.
Limitations of the current study include potential
selection bias and/or birth cohort effects. The preva-
lence of obesity in the current study was 30, 38, and
8% in the young, aged, and nonagenarians groups,
respectively. As such, more individuals from the
younger groups may have been “unhealthier” with
increased risk of disease thereby diluting differences
that would have otherwise been observed. In addition,
there were extensive exclusion criteria in order to
prevent the confounding effects of existing disease,
which may have influenced the study variables. The
disadvantage to this is that we may have biased our
sample towards a healthier population of older
individuals. Consequently, our results should be
interpreted with caution.
Conclusion
In conclusion, nonagenarians had less prevalence of
the metabolic syndrome and cardiovascular risk
factors, which were comparable, if not lower, to those
of individuals aged 60–74 years, indicating that their
longevity may occur as a result of their biological
resistance—probably genetically determined—to dis-
ease. Furthermore, the low prevalence of metabolic
syndrome in the nonagenarians was not directly
related to reduced inflammation and accumulation of
oxidative stress.
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